3-Chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyridine

Catalog No. :
ACIXQB092
CAS No. :
1217013-38-1
Molecular Formula :
C11H11ClF3NO2
Molecular Weight :
281.66

IUPAC Name:3-chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyridine

3-Chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$256.00Login to see priceInquiryInquiry
5g97%$768.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyridine
IUPAC Name3-chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(trifluoromethyl)pyridine
Molecular FormulaC11H11ClF3NO2
Molecular Weight281.66
SMILESFC(C1=CN=C(OC2CCOCC2)C(Cl)=C1)(F)F
InChI KeyAMDOFYFKWLAPGN-UHFFFAOYSA-N
Synonym3-chloro-2-(tetrahydro-2H-pyran-4-yloxy)-5-(trifluoromethyl)pyridine;Pyridine, 3-chloro-2-[(tetrahydro-2H-pyran-4-yl)oxy]-5-(trifluoromethyl)-
CAS No.1217013-38-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACIXQB092 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBLIJ086 route compound structure diagram
    ACBLIJ0862081-44-9 In Stock
  4. Then
  5. ACIXQB092 route product structure diagram
    ACIXQB0921217013-38-1
Inquiry

2. ACIXQB092 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBLIJ086 route compound structure diagram
    ACBLIJ0862081-44-9 In Stock
  4. Then
  5. ACIXQB092 route product structure diagram
    ACIXQB0921217013-38-1
Inquiry

Comments (0)